Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group
Corte, J.R., Fang, T., Pinto, D.J.P., Orwat, M.J., Han, W., Rendina, A.R., Luettgen, J.M., Rossi, K.A., Wei, A., Ramamurthy, V., Myers Jr., J.E., Sheriff, S., Narayanan, R., Harper, T., Zheng, J.J., Li, Y.-X., Seiffert, D.A., Wexler, R.R., Quan, M.L.(2016) Bioorg Med Chem 24: 2257-2272
- PubMed: 27073051 
- DOI: 10.1016/j.bmc.2016.03.062
- Primary Citation of Related Structures:  
5EXM, 5EXL, 5EXN - PubMed Abstract: 
Pyridine-based Factor XIa (FXIa) inhibitor (S)-2 was optimized by modifying the P2 prime, P1, and scaffold regions. This work resulted in the discovery of the methyl N-phenyl carbamate P2 prime group which maintained FXIa activity, reduced the number of ...